South Korea’s pharmaceutical industry has moved beyond a phase of rapid domestic growth and now faces the challenge of strengthening its global competitiveness. As competition in drug development intensifies, Chong Kun Dang is reinforcing its research and development (R&D) capabilities, manufacturing infrastructure and financing capacity to support long-term growth.
According to industry sources on June 12, Chong Kun Dang has steadily increased its investment in R&D in recent years. One of the most notable examples is a large-scale research complex currently being developed in the Baegot district of Siheung, Gyeonggi Province.
The company disclosed on June 11 that it approved a new facilities investment of approximately $286 million to build the Baegot Bio Research Complex.
The investment represents approximately 39% of Chong Kun Dang’s shareholders’ equity, which totaled about $775 million under its consolidated K-IFRS financial statements as of Dec. 31, 2025. Construction is scheduled to begin following the board’s approval and continue through the expected completion date of Aug. 31, 2028.
The development site is located in the Baegot Research Zone 3-1 area at 302 Baegot-dong and spans approximately 79,791 square meters (about 19.7 acres). Chong Kun Dang had previously been selected as the preferred bidder for the site as part of plans to establish a large-scale biotechnology campus.
The company intends to develop the complex into a future R&D hub supporting new drug development, open innovation initiatives and collaborations with universities and research institutions.
Industry observers view the project as more than a research facility, describing it as a centerpiece of Chong Kun Dang’s long-term growth strategy.
Chong Kun Dang has also been actively expanding into the contract development and manufacturing organization (CDMO) sector.
The CDMO business is widely viewed as a strategic growth area because it can expand partnerships with global pharmaceutical companies and create opportunities for overseas market expansion.
As demand for biologic drugs continues to grow rapidly, manufacturing capacity is increasingly seen as a key competitive advantage. Industry analysts say the company’s proactive investments are aimed at positioning it to meet future demand.
The company has also secured financing to support its large-scale investment plans. Chong Kun Dang recently signed a $730 million financing agreement with Woori Bank.
The agreement is expected to strengthen the company’s financial foundation for R&D, manufacturing facility investments and global expansion initiatives.
“Whereas company size and domestic sales once determined competitiveness, today R&D investment, manufacturing capabilities and global networks are the key drivers of corporate value,” an industry official said. “Chong Kun Dang is strengthening all three areas simultaneously to prepare for future growth.”
Challenges remain as the company competes against established global pharmaceutical and CDMO players.
Still, industry observers say Chong Kun Dang could emerge as a globally competitive innovative pharmaceutical company if its investments in R&D, manufacturing infrastructure and financing continue to reinforce one another.
Another industry executive said, “As pharmaceuticals become increasingly recognized as a future growth engine for the country, Chong Kun Dang’s strategy is meaningful not only for the company itself but also for enhancing the competitiveness of South Korea’s pharmaceutical industry as a whole.”
